NCT04370457

Brief Summary

Randomized unblinded interventional clinical trial: Arm Intervention Experimental arm (n=150): Intervention group Administration of the MyPal ePRO system the intervention group will use the ePRO tools provided in the project. Standard care arm (n=150): no intervention besides general palliative care if required general palliative care if required. Patients will be randomly assigned in a 1:1 fashion to use the MyPal system and receive related-intervention versus general palliative care, stratified by cancer type (i.e. CLL vs MDS), using a computer-generated number sequence, which will be concealed until after group assignment.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
300

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Jan 2021

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 25, 2020

Completed
6 days until next milestone

First Posted

Study publicly available on registry

May 1, 2020

Completed
8 months until next milestone

Study Start

First participant enrolled

January 1, 2021

Completed
1.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 30, 2022

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

September 30, 2022

Completed
Last Updated

August 4, 2021

Status Verified

July 1, 2021

Enrollment Period

1.5 years

First QC Date

April 25, 2020

Last Update Submit

August 3, 2021

Conditions

Outcome Measures

Primary Outcomes (2)

  • Improvement in EORTC Quality of Life Questionnaire (QLQ)-C30 General Questionnaire

    The primary objective is to determine whether - compared to standard care - the MyPal-ADULT intervention can lead to improved QoL as evidenced by statistically significant higher scores in EORTC Quality of Life Questionnaire (QLQ)-C30 General Questionnaire

    through study completion, an average of 1 year

  • Improvement in EuroQol (EQ)-five dimensions (5D)

    The primary objective is to determine whether - compared to standard care - the MyPal-ADULT intervention can lead to improved QoL as evidenced by statistically significant higher scores in EuroQol (EQ)-five dimensions (5D).

    through study completion, an average of 1 year

Study Arms (2)

Experimental arm

EXPERIMENTAL

Administration of the MyPal ePRO system

Other: Administration of the MyPal ePRO system

Standard care arm

NO INTERVENTION

No further intervention besides standard palliative care approach if needed

Interventions

Patients will be asked to complete self-report questionnaires at baseline, and every month for the first six months and at 12-month follow-up

Experimental arm

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Adults (≥18 years)
  • Diagnosed with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) or myelodysplastic syndrome (MDS)
  • Scheduled to receive any line of treatment for CLL/SLL or MDS or who have been previously exposed to any treatment for CLL or MDS
  • Able to understand and communicate in the respective language
  • Users of an Internet connected device (smart phone/tablet)

You may not qualify if:

  • Patients who are already participating in another experimental study
  • Patients needing immediate referral for specialized palliative care
  • Any life-threatening illness, medical condition, or organ system dysfunction that, in the investigator's opinion, could compromise the subject's safety or put the study outcomes at undue risk
  • Patients unable to provide written informed consent
  • Life expectancy \<3 months
  • For CLL cohort: patients who have experienced Richter transformation

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

IRCCS Ospedale San Raffaele

Milan, 20132, Italy

RECRUITING

Related Publications (3)

  • Chatzikonstantinou T, Vasilopoulou M, Kyrou D, Karakatsoulis G, Argyropaidas P, Besikli-Dimou S, Bonotis P, Chatzimina M, Didi J, Dimosthenous C, Garani-Papadatos T, Hoffman S, Kakalou C, Kazantzaki E, Kiefer S, Koumakis L, Ling J, Maramis C, Meyerheim M, Payne C, Papangelou C, Payne S, Pontikoglou C, Reston R, Ryblom H, Sander A, Schera F, Smedby KE, Zacharioudakis G, Chatzidimitriou A, Doubek M, Stavroyianni N, Ghia P, Papadaki HA, Rosenquist R, Graf N, Natsiavas P, Stamatopoulos K, Karamanidou C, Scarfo L. Assessing an eHealth Intervention on Quality of Life in Patients With Chronic Lymphocytic Leukemia and Myelodysplastic Syndromes: The MyPal Randomized Controlled Trial. JCO Oncol Pract. 2025 Aug 25:OP2500087. doi: 10.1200/OP-25-00087. Online ahead of print.

  • Payne S, Begovic D, Salifu Y, Nelson A, Payne C, Downing J, Natsiavas P, Ling J. Applying Digital Health in Cancer and Palliative Care in Europe: Policy Recommendations from an International Expert Workshop (MyPal Project). J Palliat Med. 2024 Feb;27(2):216-223. doi: 10.1089/jpm.2023.0309. Epub 2023 Sep 22.

  • Scarfo L, Karamanidou C, Doubek M, Garani-Papadatos T, Didi J, Pontikoglou C, Ling J, Payne C, Papadaki HAlpha, Rosenquist R, Stavroyianni N, Payne S, Ghia P, Natsiavas P, Maramis C, Stamatopoulos K. MyPal ADULT study protocol: a randomised clinical trial of the MyPal ePRO-based early palliative care system in adult patients with haematological malignancies. BMJ Open. 2021 Nov 2;11(11):e050256. doi: 10.1136/bmjopen-2021-050256.

MeSH Terms

Conditions

Leukemia, Lymphocytic, Chronic, B-CellMyelodysplastic Syndromes

Condition Hierarchy (Ancestors)

Leukemia, B-CellLeukemia, LymphoidLeukemiaNeoplasms by Histologic TypeNeoplasmsHematologic DiseasesHemic and Lymphatic DiseasesLymphoproliferative DisordersLymphatic DiseasesImmunoproliferative DisordersImmune System DiseasesChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and SymptomsBone Marrow Diseases

Study Officials

  • Paolo Ghia, MD,PhD

    IRCCS San Raffaele

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Paolo Ghia, Prof.

CONTACT

Eloise Scarano, Dr

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 25, 2020

First Posted

May 1, 2020

Study Start

January 1, 2021

Primary Completion

June 30, 2022

Study Completion

September 30, 2022

Last Updated

August 4, 2021

Record last verified: 2021-07

Data Sharing

IPD Sharing
Will not share

Locations